Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways & Drug Targets in Systemic Lupus Erythematosus

On Tuesday, November 15, during the 2016 ACR/ARHP Annual Meeting, Dr Peter Lipsky will give a talk entitled “Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways & Drug Targets in Systemic Lupus Erythematosus” during the “Mining Big Data for Drug Repurposing” session. The presentation will begin at 11:00 AM in room 146A.

For more information visit:

Data mining could lead to therapy advances

In the past 50 years, only one new therapy has been approved for the treatment of lupus.

Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.

The symposium will take place from 11:00 am – 12:00 pm on Tuesday in room 146A and will demonstrate the potential role of genetics and data mining strategies in identifying new or repurposed therapeutic targets for systemic autoimmune rheumatic diseases.

Read more…

Senator Creigh Deeds Stopped by AMPEL BioSolutions

  • October 28, 2016
  • News

Today, Senator Creigh Deeds stopped by AMPEL BioSolutions to visit with our employees and learn about how we are using Big Data to find and test new drugs for lupus patients. He got to see first-hand how our research is helping patients and their families have hope. We are very impressed with the questions Senator Deeds asked and his commitment to strengthening our biotechnology community here in Charlottesville.

AMPEL Particpates in UVA Fall Job and Internship Fair

  • October 28, 2016
  • News

On October 26 and 27, 2016 AMPEL participated in the Fall Job and Internship Fair hosted by the University of Virginia. To read more about this event visit:

Grammer, far right, with her team from AMPEL BioSolutions, including from left to right, UVA alumnus Adam Labonte, Nick Geraci, Prathyusha Bachali, alumna Sarah Heuer and Rebecca Bender.

New Results Published Demonstrate Effectiveness of AMPEL’s Innovative System

New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases. Funded by the Lupus Research Alliance and the John and Marcia Goldman Foundation, the study used Big Data to confirm selection of potential treatments identified by analyzing data on over 1,000 drugs approved by the U.S. Food and Drug Administration and eliciting broad feedback via internet crowd-sourcing.

The LRxL-STAT (Lupus Treatment List-SLE Treatment Acceleration Trials) was initiated by the Lupus Research Alliance) with Drs. Peter Lipsky and Amrie Grammer of AMPEL BioSolutions to address the urgent need for safer, more effective lupus treatments.

Click here to read the full article.